Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sansure BiotechSHSE:688289 +0.77%69 Debt-to-EBITDA is 3.66 as of Jun. 2026, which is 7220% above its 10-year median of 0.05. GuruFocus rates SHSE:688289 with a GF Score™ of 69/100 and a GF Value™ of ¥22.67 (Significantly Undervalued). The stock has 7 warning signs investors should review. Among 471 Medical Devices & Instruments companies, Sansure Biotech ranks worse than 94.06% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Sansure Biotech's Debt-to-EBITDA or its related term are showing as below:
SHSE:688289'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.01 Med: 0.05 Max: 12.02
Current: 12.02
During the past 9 years, the highest Debt-to-EBITDA Ratio of Sansure Biotech was 12.02. The lowest was 0.01. And the median was 0.05.
SHSE:688289's Debt-to-EBITDA is ranked worse than 94.06% of 471
companies
in the Medical Devices & Instruments industry
Industry Median: 1.64
vs SHSE:688289: 12.02
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Sansure Biotech Debt-to-EBITDA Related Terms
Sansure Biotech Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Sansure Biotech's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:688289 vs ISRG, BDX, RMD: Debt-to-EBITDA Comparison
For the Medical Instruments & Supplies subindustry, Sansure Biotech's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sansure Biotech Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sansure Biotech's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Sansure Biotech's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
Sansure Biotech (SHSE:688289) has a Debt-to-EBITDA of 3.66 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Sansure Biotech. This is 7220% above median its historical median of 0.05. Over the past decade, Sansure Biotech's Debt-to-EBITDA has ranged from 0.01 to 12.02. According to the industry distribution chart, Sansure Biotech ranks #443 out of 471 companies in the Medical Devices & Instruments industry, placing it in the top 94.1%.
Is Sansure Biotech's Debt-to-EBITDA too high?
Sansure Biotech's current Debt-to-EBITDA of 3.66 is 7220% above median its 10-year median of 0.05. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 12.02. The Medical Devices & Instruments industry median Debt-to-EBITDA is 1.64. Sansure Biotech's value of 3.66 is 123.2% above this industry median. Based on the distribution chart, Sansure Biotech ranks #443 out of 471 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Sansure Biotech has a GF Score™ of 69/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sansure Biotech's Debt-to-EBITDA compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Sansure Biotech ranks #443 out of 471 companies for Debt-to-EBITDA. This places Sansure Biotech in the lower half of its industry. The industry median Debt-to-EBITDA is 1.64. Sansure Biotech's value of 3.66 is 123.2% above this benchmark. Historically, Sansure Biotech's own Debt-to-EBITDA has ranged from 0.01 to 12.02 over the past decade. While the company's 10-year median is 0.05 vs. the industry median of 1.64, Sansure Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.64, based on 471 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sansure Biotech's current Debt-to-EBITDA of 3.66 is 123.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Sansure Biotech. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sansure Biotech's current Debt-to-EBITDA is 3.66, which is 7220% above median its own 10-year median of 0.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sansure Biotech stock overvalued right now?
Based on GuruFocus' analysis, Sansure Biotech (SHSE:688289) is currently considered Significantly Undervalued. The stock's GF Value™ is ¥22.67, compared to a current price of ¥15.64 — trading 31% below its estimated fair value. The current Debt-to-EBITDA is 3.66, which is 7220% above median its 10-year median of 0.05 and 123.2% above the Medical Devices & Instruments industry median of 1.64. Sansure Biotech's overall GF Score™ is 69/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Sansure Biotech (SHSE:688289), the current Debt-to-EBITDA is 3.66 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sansure Biotech (SHSE:688289) Overvalued in 2026?
Based on GuruFocus' analysis, Sansure Biotech stock appears to be undervalued.
The current stock price of ¥15.64 is trading 31% below its estimated GF Value™ of ¥22.67.
GuruFocus considers Sansure Biotech to be Significantly Undervalued.
Key valuation signals for SHSE:688289:
Debt-to-EBITDA: 3.66 (7220% above median its 10-year median of 0.05)
GF Value™: ¥22.67 vs. price of ¥15.64 (31% below fair value)
Industry Position: 123.2% above the Medical Devices & Instruments median (#443 of 471)
No single metric tells the full story. See the SHSE:688289 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688289 has been successfully added to your 
